Prof. Dr. med. Thomas Benzing
Department II of Internal Medicine
University Hospital Cologne
Kerpener Str. 62
50937 Cologne, Germany
thomas.benzing@uk-koeln.de
Prof. Dr. med. Paul Thomas Brinkkötter
Department II of Internal Medicine
University Hospital Cologne
Kerpener Str. 62
50937 Cologne, Germany
paul.brinkkoetter@uk-koeln.de

KFO 329

Disease pathways in podocyte injury – from molecular mechanisms to individualized treatment options

The Clinical Research Unit (CRU) 329 "Disease pathways in podocyte injury – from molecular mechanisms to individualized treatment options" is an interdisciplinary, cross faculty research center of excellence funded through the Deutsche Forschungsgemeinschaft (DFG). 

This CRU is based on the concept that minimal-change disease and focal-segmental glomerulosclerosis (FSGS) treatment require a targeted approach that addresses the particular underlying pathogenic mechanism in each individual case. The overall aim of this CRU is to develop diagnostic tools and to characterize pathogenic pathways to allow individualized treatment approaches targeting the distinct pathomechanisms. Thus, we aim to convert FSGS management from a trial-and-error approach into a precision medicine strategy based on targeting individual disease mechanisms in patients.